课题基金 / 基金详情

Probing Cardiovascular Actions of GLP-1 Using Nanoparticles

Probing Cardiovascular Actions of GLP-1 Using Nanoparticles
使用纳米颗粒探索 GLP-1 的心血管作用
批准号:
9914122
负责人:
Andrei Maiseyeu
金额:
$39.63万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-05-01 至 2022-04-30
关键词:
AccountingAcuteAddressAgonistAlkynesAntiatherogenicAntidiabetic DrugsAntihypertensive AgentsAntiinflammatory EffectArterial Fatty StreakArtificial nanoparticlesAtherosclerosisAttenuatedAvidityAzidesBloodBlood GlucoseBlood PressureBody Weight decreasedCD36 geneCadherinsCardiovascular AgentsCardiovascular DiseasesCardiovascular systemCellsCessation of lifeChemotaxisCholesterolChronicClinicClinicalClinical ResearchDataDendritic CellsDetectionDevelopmentDrug Delivery SystemsEatingEmigrationsEventFibratesFlow CytometryFoam CellsFutureGadoliniumGene ExpressionGlucoseGoalsHormonesHyperglycemiaHypertensionImageImmuneInflammationInflammatoryInsulin ResistanceLabelLaboratoriesLesionLeukocytesLipidsLiverMagnetic Resonance ImagingMeasurableMessenger RNAModalityModelingModernizationModificationMolecularMusMyeloid CellsMyocardial InfarctionNTN1 geneNon-Insulin-Dependent Diabetes MellitusOGTTOrganPancreasPatientsPermeabilityPharmaceutical PreparationsPharmacologic SubstancePhenotypePublic HealthRegression AnalysisReportingResearch PersonnelRisk FactorsSafetySemaphorinsSignal TransductionStainsStrokeSumTechnologyTestingTherapeuticTranscriptTreatment Protocolsbaseblood lipidcardiovascular disorder riskcell behaviordiabetes mellitus therapydiabeticdiabetic patienteffective interventionfluorophoreglucagon-like peptide 1glycemic controlimprovedin vitro Assayin vivoinsulin sensitivitylaser capture microdissectionliraglutidemacrophagemimeticsmonocytemortalitynanoparticlenanoparticle deliverynon-drugnovel therapeuticsoxidized lipidparticlepeptidomimeticspleiotropismreceptorrecruittargeted imagingtooltreatment effecttreatment strategyvascular abnormality

项目摘要

项目成果

Andrei Maiseyeu的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 高血糖是2型糖尿病(T2D)的标志,并加速 动脉粥样硬化,这反过来又先于主要心血管并发症的发展。在人身上 对于T2D,心血管疾病对死亡率的贡献很大,占T2D的65%到80% 死亡。治疗心血管疾病的降糖药物的研究进展 因此,疾病是一个优先事项。然而,目前的心血管药物(他汀类、贝特类、抗高血压药)是 在T2D中仅有中等疗效,部分原因是这些药物不能完全解决某些血管问题 异常,如炎症、泡沫细胞形成和白细胞向动脉壁聚集。 因此,需要更有效的干预措施来同时治疗高血糖和动脉粥样硬化。 本研究旨在阐明高血糖素样多肽-1(GLP-1)在血管内皮细胞中表达的分子机制。 通过使用针对动脉粥样硬化并对其成像的纳米颗粒探针来治疗心血管疾病。GLP-1是 一种内源性肠源性激素,目前在临床上以多肽模拟物的形式使用,可提供 T2D患者的血糖控制。我们和其他研究人员已经证明,GLP-1对 对免疫细胞有多种影响,并有可能减少动脉粥样硬化。我们推测GLP-1可能 通过激活其受体GLP-1R直接调节免疫细胞的行为,从而减少单核细胞 聚集到斑块,增强巨噬细胞和胆固醇的排出,并化解炎症。为了 分离GLP-1对动脉粥样硬化免疫细胞的作用及降糖作用 需要有效的药物输送系统,以促进GLP-1在皮损白细胞中的积聚。我们 建议使用将成像的工程纳米颗粒来研究GLP-1的基因位点特异性作用 皮损和血液白细胞同时提供斑块内GLP-1模拟物的有效载荷。这 核磁共振可见纳米颗粒保留后,技术可激活斑块中的药物释放 在吃我信号的帮助下。GLP-1抗动脉粥样硬化作用的潜在机制是 通过实现两个具体目标进行评估: 特异性目标1将确定被靶向的白细胞的炎症和迁移表型 纳米颗粒或单独使用GLP-1。在这里,我们将评估GLP-1对免疫细胞的急性影响。 具体目标2将确定GLP-1的抗动脉粥样硬化作用是由脂质作用还是抗炎作用决定的。这里, 我们将研究动脉粥样硬化的抑制依赖于GLP-1的传递位置 治疗方案。GLP-1的器官特异性作用将通过按需纳米颗粒传递来探索 现代聚乙二醇化技术。 总而言之,这项建议的意义在于它解决了改善治疗的迫切临床需求 针对高血糖和动脉粥样硬化的策略。
英文摘要
Project Summary Hyperglycemia is the hallmark of type 2 diabetes (T2D) and accelerates the development of atherosclerosis, which, in turn, precedes the development of major cardiovascular complications. In people with T2D, cardiovascular disease significantly contributes to mortality, accounting for 65%-to-80% of T2D deaths. The development of pharmaceutical agents that lower glucose while also treating cardiovascular disease is therefore a priority. However, current cardiovascular agents (statins, fibrates, antihypertensives) are only moderately efficacious in T2D, partly because these agents incompletely address certain vascular abnormalities, such as inflammation, foam cell formation and leukocyte recruitment to the arterial wall. Therefore, more effective interventions are needed that treat both hyperglycemia and atherosclerosis. The goal of this proposal is to elucidate the molecular mechanisms of glucagon-like peptide-1 (GLP-1) in cardiovascular disease through the use of nanoparticle probes that target and image atherosclerosis. GLP-1 is an endogenous gut-derived hormone presently used in clinics in the form of peptide mimetics that provide glycemic control in patients with T2D. We and other investigators have demonstrated that GLP-1 exerts a multitude of effects on immune cells and has the potential to reduce atherosclerosis. We posit that GLP-1 may directly regulate immune cell behavior by activating its receptor, GLP-1R, thereby reducing monocyte recruitment to the plaque, potentiating macrophage and cholesterol exit, and resolving inflammation. In order to isolate glucose lowering and systemic effects of GLP-1 from its actions on immune cells in atherosclerosis, an effective drug delivery system would be required that favors accumulation of GLP-1 in lesional leukocytes. We propose to investigate locus-specific actions of GLP-1 with the use of engineered nanoparticles that will image lesional and blood leukocytes simultaneously delivering a payload of a GLP-1 mimetic within plaque. This technology activates the drug release in the plaque following the retention of MRI-visible nanoparticles facilitated by eat-me signals. The underlying mechanisms of the anti-atherogenic effects of GLP-1 will be evaluated by carrying out two specific aims: Specific aim 1 will determine the inflammatory and migratory phenotype of leukocytes that were targeted by nanoparticles or GLP-1 alone. Here we will assess acute effects of GLP-1 on immune cells. Specific aim 2 will define whether lipid or anti-inflammatory effects govern anti-atherogenicity of GLP-1. Here, we will investigate atherosclerosis inhibition depending on the locus of GLP-1 delivery following chronic treatment regimen. Organ-specific actions of GLP-1 will be explored using on-demand nanoparticle delivery via modern pegylation technologies. In sum, the significance of this proposal is that it addresses an urgent clinical need for improved treatment strategies targeting both hyperglycemia and atherosclerosis.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1080/10717544.2021.1886199
发表时间: 2021-12
期刊: Drug delivery
影响因子: 6
作者: [Di L, Maiseyeu A]
通讯作者: Maiseyeu A
Non-antigenic regulators of targeting for imaging and therapy.
成像和治疗靶向的非抗原调节剂。
DOI: 10.1016/j.addr.2016.02.009
发表时间: 2016
期刊: Advanced drug delivery reviews
影响因子: 16.1
作者: [Maiseyeu,Andrei]
通讯作者: Maiseyeu,Andrei
Facile Cholesterol Loading with a New Probe ezFlux Allows for Streamlined Cholesterol Efflux Assays.
使用新探针 ezFlux 轻松加载胆固醇,可简化胆固醇流出测定。
DOI: 10.1021/acsomega.0c03112
发表时间: 2020
期刊: ACS omega
影响因子: 4.1
作者: [Ravodina,AnastasiaM, Badgeley,MarcusA, Rajagopalan,Sanjay, Fedyukina,DariaV, Maiseyeu,Andrei]
通讯作者: Maiseyeu,Andrei
Targets and targeting of immunometabolism in chronic PM2.5 exposure
  • 批准号:
    10563199
  • 项目类别:
  • 资助金额:
    $40.25万
  • 财政年份:
    2022
  • 负责人:
    Andrei Maiseyeu
  • 依托单位:
Targets and targeting of immunometabolism in chronic PM2.5 exposure
  • 批准号:
    10349277
  • 项目类别:
  • 资助金额:
    $40.25万
  • 财政年份:
    2022
  • 负责人:
    Andrei Maiseyeu
  • 依托单位:
Non-racemic metabolic biomaterials for HFpEF
  • 批准号:
    10295348
  • 项目类别:
  • 资助金额:
    $40.25万
  • 财政年份:
    2021
  • 负责人:
    Andrei Maiseyeu
  • 依托单位:
Non-racemic metabolic biomaterials for HFpEF
  • 批准号:
    10677638
  • 项目类别:
  • 资助金额:
    $40.25万
  • 财政年份:
    2021
  • 负责人:
    Andrei Maiseyeu
  • 依托单位:
海外基金